![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/05/2894264/33485/en/Xenon-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/09/2879120/33485/en/Xenon-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/07/2877183/33485/en/Xenon-Pharmaceuticals-to-Present-at-the-2024-RBC-Capital-Markets-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/04/10/2860737/33485/en/Xenon-Pharmaceuticals-to-Present-at-the-2024-Bloom-Burton-Co-Healthcare-Investor-Conference.html
https://www.globenewswire.com//news-release/2023/12/04/2790471/33485/en/Xenon-Pharmaceuticals-Announces-Closing-of-345-0-Million-Upsized-Public-Offering-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com/news-release/2023/12/02/2789643/33485/en/Xenon-Pharmaceuticals-Provides-Updates-on-Neurology-Pipeline-Programs-at-the-Annual-Meeting-of-the-American-Epilepsy-Society-AES-2023.html
https://endpts.com/xenon-offers-300m-in-shares-after-touting-path-ahead-for-mdd-program-despite-phii-miss/
https://www.globenewswire.com//news-release/2023/11/30/2788212/33485/en/Xenon-Pharmaceuticals-Announces-Pricing-of-Upsized-300-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/29/2788081/33485/en/Xenon-Pharmaceuticals-Announces-Proposed-Public-Offering.html
https://www.fiercebiotech.com/biotech/xenon-pharmaceuticals-major-depressive-med-fails-ph-2-eyes-more-fixated-seizure-potential